Department of Nuclear Medicine.
Department of Gynaecology, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, Guangdong, P.R. China.
Medicine (Baltimore). 2021 Apr 30;100(17):e25612. doi: 10.1097/MD.0000000000025612.
Metastatic prostate carcinoma has poor prognoses with a median survival period ranging from 2 to 5 years with existing therapeutic challenges. Currently, peptide receptor radionuclide therapy is permitted as a treatment method for metastatic prostate carcinoma patients. Therefore, it is crucial to comprehend the efficiency and safety of peptide receptor radionuclide therapy among this patient population. This study aims to analyse the efficacy of peptide receptor radionuclide therapy when used to treat metastatic prostate carcinoma patients.
This research will perform a methodological search in the following electronic databases to find related randomized controlled trials: Cochrane Library, EMBASE, PubMed, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), WanFang database, and Chinese BioMedical Literature. All the databases are searched from their inauguration till November 2020. Two independent authors will screen and select literature for review. The two authors will independently utilize the Cochrane Risk of Bias tool to assess the bias risk in studies. This study also plans to conduct subgroup and sensitivity analyses to evaluate the robustness in the results. Statistical analyses will be conducted with the RevMan 5.3 software.
A high-quality synthesis of existing evidence related to peptide receptor radionuclide therapy in the treatment of metastatic prostate carcinoma will be presented in this study.
Our findings will provide evidence to judge whether peptide receptor radionuclide treatment is efficient for metastatic prostate carcinoma patients.
An ethics approval is not required because the data of the present study are primarily obtained from published studies.OSF registration number: December 1, 2020.osf.io/3psx7. (https://osf.io/3psx7/).
转移性前列腺癌预后较差，中位生存期为 2 至 5 年，目前存在治疗挑战。目前，肽受体放射性核素治疗被允许作为转移性前列腺癌患者的治疗方法。因此，了解这种患者群体中肽受体放射性核素治疗的效率和安全性至关重要。本研究旨在分析肽受体放射性核素治疗转移性前列腺癌患者的疗效。
本研究将在以下电子数据库中进行方法学搜索，以找到相关的随机对照试验：Cochrane 图书馆、EMBASE、PubMed、Web of Science、Scopus、中国国家知识基础设施（CNKI）、万方数据库和中国生物医学文献。所有数据库均从成立之日起搜索至 2020 年 11 月。两名独立作者将筛选和选择文献进行综述。两名作者将独立使用 Cochrane 偏倚风险工具评估研究中的偏倚风险。本研究还计划进行亚组和敏感性分析，以评估结果的稳健性。统计分析将使用 RevMan 5.3 软件进行。
本研究将对肽受体放射性核素治疗转移性前列腺癌的现有证据进行高质量综合。
我们的研究结果将为判断肽受体放射性核素治疗是否对转移性前列腺癌患者有效提供证据。
由于本研究的数据主要来自已发表的研究，因此不需要伦理批准。OSF 注册号：2020 年 12 月 1 日，osf.io/3psx7（https://osf.io/3psx7/）。
